Federal Register / Vol. 61, No. 130 / Friday, July 5, 1996 / Notices 35231

concerning the policy and procedures

for electronic media coverage of FDA’s

public administrative proceedings,

including hearings before public

advisory committees under 21 CFR part

14. Under 21 CFR 10.205,

representatives of the electronic media

may be permitted, subject to certain

limitations, to videotape, film, or

otherwise record FDA’s public

administrative proceedings, including

presentations by participants.

Meetings of advisory committees shall

be conducted, insofar as is practical, in

accordance with the agenda published

in this Federal Register notice. Changes

in the agenda will be announced at the

beginning of the open portion of a

meeting.

Any interested person who wishes to

be assured of the right to make an oral

presentation at the open public hearing

portion of a meeting shall inform the

contact person listed above, either orally

or in writing, prior to the meeting. Any

person attending the hearing who does

not in advance of the meeting request an

opportunity to speak will be allowed to

make an oral presentation at the

hearing’s conclusion, if time permits, at

the chairperson’s discretion.

The agenda, the questions to be

addressed by the committee, and a

current list of committee members will

be available at the meeting location on

the day of the meeting.

Transcripts of the open portion of the

meeting may be requested in writing

from the Freedom of Information Office

(HFI–35), Food and Drug

Administration, 5600 Fishers Lane, rm.

12A–16, Rockville, MD 20857,

approximately 15 working days after the

meeting, at a cost of 10 cents per page.

The transcript may be viewed at the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, approximately 15

working days after the meeting, between

the hours of 9 a.m. and 4 p.m., Monday

through Friday. Summary minutes of

the open portion of the meeting may be

requested in writing from the Freedom

of Information Office (address above)

beginning approximately 90 days after

the meeting.

This notice is issued under section

10(a)(1) and (2) of the Federal Advisory

Committee Act (5 U.S.C. app. 2), and

FDA’s regulations (21 CFR part 14) on

advisory committees.

Dated: June 28, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–17170 Filed 7–3–96; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

Agency Information Collection

Activities: Proposed Collection:

Comment Request

In compliance with the requirement

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Health Care Financing Administration

(HCFA), Department of Health and

Human Services, has submitted to the

Office of Management and Budget

(OMB) the following proposals for the

collection of information. Interested

persons are invited to send comments

regarding this burden estimate or any

other aspect of this collection of

information, including any of the

following subjects: (1) The necessity and

utility of the proposed information

collection for the proper performance of

the agency’s functions; (2) the accuracy

of the estimated burden; (3) ways to

enhance the quality, utility, and clarity

of the information to be collected; and

(4) the use of automated collection

techniques or other forms of information

technology to minimize the information

collection burden.

1. Type of Request: Extension of a

currently approved collection; Title of

Information Collection: Information

Collection Requirements contained in

42 CFR 447.253; Form No.: HCFA-R–

117; Use: In order to receive HCFA

approval of a Medicaid State plan

amendment which changes the methods

and standards used to establish payment

rates for inpatient hospital or long-term

care services, a Medicaid State Agency

must provide a statement which assures

the HHS Secretary that the resulting

rates will conform to all the

requirements specified in section

1902(a)(13)(A) of the Social Security Act

and implementing regulations at 42 CFR

447.253; Frequency: Annually; Affected

Public: State, local, or tribal

government; Number of Respondents:

54; Total Annual Responses: 54; Total

Annual Hours: 54.

To request copies of the proposed

paperwork collection referenced above,

E-mail your request, including your

address, to Paperwork@hcfa.gov, or call

the Reports Clearance Office on (410)

786–1326. Written comments and

recommendations for the proposed

information collections should be sent

within 60 days of this notice directly to

the HCFA Paperwork Clearance Officer

designated at the following address:

HCFA, Office of Financial and Human

Resources, Management Planning and

Analysis Staff, Attention: Linda

Mansfield, Room C2–26–17, 7500

Security Boulevard, Baltimore,

Maryland 21244–1850.

Dated: June 27, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis

Staff, Office of Financial and Human

Resources, Health Care Financing

Administration.

[FR Doc. 96–17126 Filed 7–03–96; 8:45 am]

BILLING CODE 4120–03–P

[R-138]

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

In compliance with the requirement

of section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995, the

Health Care Financing Administration

(HCFA), Department of Health and

Human Services, has submitted to the

Office of Management and Budget

(OMB) the following proposal for the

collection of information. Interested

persons are invited to send comments

regarding the burden estimate or any

other aspect of this collection of

information, including any of the

following subjects: (1) The necessity and

utility of the proposed information

collection for the proper performance of

the agency’s functions; (2) the accuracy

of the estimated burden; (3) ways to

enhance the quality, utility, and clarity

of the information to be collected; and

(4) the use of automated collection

techniques or other forms of information

technology to minimize the information

collection burden.

Type of Information Collection

Request: Reinstatement, with change, of

a previously approved collection for

which approval has expired; Title of

Information Collection: Medicare

Geographical Classification Review

Board (MGCRB) Procedures and

Criteria; Form No.: HCFA-R-138; Use:

This regulation sets up an application

process for prospective payment system

hospitals who choose to appeal their

geographic status to the Medicare

Geographic Classification Review Board

(MGCRB). This regulation also

establishes procedural guidelines for the

MGCRB. Frequency: Annually; Affected

Public: Business or other for profit, and

Not for profit institutions; Number of

Respondents: 1,000; Total Annual

Responses: 1,000; Total Annual Hours

Requested: 1,000.

To request copies of the proposed

paperwork collections referenced above,

E-mail your request, including your

address, to Paperwork@hcfa.gov, or call

the Reports Clearance Office on (410)

786-1326. Written comments and

recommendations for the proposed

information collections should be sent

within 30 days of this notice directly to
35232 Federal Register / Vol. 61, No. 130 / Friday, July 5, 1996 / Notices

the OMB Desk Officer designated at the

following address: OMB Human

Resources and Housing Branch,

Attention: Allison Eydt, New Executive

Office Building, Room 10235,

Washington, D.C. 20503.

Dated: June 27, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis

Staff, Office of Financial and Human

Resources, Health Care Financing

Administration.

[FR Doc. 96–17127 Filed 7–03–96; 8:45 am]

BILLING CODE 4120–03–P

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies, and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS

(Formerly: National Institute on Drug

Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and

will be omitted from the monthly listing

thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh, Division of Workplace

Programs, Room 13A–54, 5600 Fishers

Lane, Rockville, Maryland 20857; Tel.:

(301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

Aegis Analytical Laboratories, Inc., 624

Grassmere Park Rd., Suite 21,

Nashville, TN 37211, 615–331–5300.

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931/205–263–5745.

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

22021, 703–802–6900.

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866.

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–

583–2787.

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–227–2783,

(formerly: Forensic Toxicology

Laboratory Baptist Medical Center).

Bayshore Clinical Laboratory, 4555 W.

Schroeder Dr., Brown Deer, WI 53223,

414–355–4444/800–877–7016.

Cedars Medical Center, Department of

Pathology, 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5810.

Centinela Hospital Airport Toxicology

Laboratory, 9601 S. Sepulveda Blvd.,

Los Angeles, CA 90045, 310–215–

6020.

Clinical Reference Lab, 11850 West 85th

St., Lenexa, KS 66214, 800–445–6917.

CompuChem Laboratories, Inc., 1904

Alexander Drive, Research Triangle

Park, NC 27709, 919–549–8263/800–

833–3984, (formerly: CompuChem

Laboratories, Inc. A Subsidiary of

Roche Biomedical Laboratory, Roche

CompuChem Laboratories, Inc., a

member of the Roche Group).

CORNING Clinical Laboratories, 4771

Regent Blvd., Irving, TX 75063, 800–

526–0947, (formerly: Damon Clinical

Laboratories, Damon/MetPath).

CORNING Clinical Laboratories, 875

Greentree Rd., 4 Parkway Ctr.,

Pittsburgh, PA 15220–3610, 800–284–

7515, (formerly: Med-Chek

Laboratories, Inc., Med-Chek/Damon,

MetPath Laboratories).

CORNING Clinical Laboratories, 24451

Telegraph Rd., Southfield, MI 48034,

800–444–0106 ext. 650 (formerly:

HealthCare/Preferred Laboratories,

HealthCare/MetPath).

CORNING Clinical Laboratories Inc.,

1355 Mittel Blvd., Wood Dale, IL

60191, 708–595–3888, (formerly:

MetPath, Inc., CORNING MetPath

Clinical Laboratories).

CORNING Clinical Laboratories, South

Central Divison, 2320 Schuetz Rd., St.

Louis, MO 63146, 800–288–7293,

(formerly: Metropolitan Reference

Laboratories, Inc.).

CORNING Clinical Laboratory, One

Malcolm Ave., Teterboro, NJ 07608,

201–393–5000, (formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories).

CORNING National Center for Forensic

Science, 1901 Sulphur Spring Rd.,

Baltimore, MD 21227, 410–536–1485,

(formerly: Maryland Medical

Laboratory, Inc., National Center for

Forensic Science).

CORNING Nichols Institute, 7470–A

Mission Valley Rd., San Diego, CA

92108–4406, 800–446–4728/619–686–

3200, (formerly: Nichols Institute,

Nichols Institute Substance Abuse

Testing (NISAT)).

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652/417–269–3093, (formerly:

Cox Medical Centers).

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, Building

38–H, Great Lakes, IL 60088–5223,

708–688–2045/708–688–4171.

Diagnostic Services Inc., dba DSI, 4048

Evans Ave., Suite 301, Fort Myers, FL

33901, 813–936–5446/800–735–5416.

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31604,

912–244–4468.

Drs. Weber, Palmer, Macy, Chartered,

338 N. Front St., Salina, KS 67401,

913–823–9246.

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

800–898–0180/206–386–2672,

(formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.).